Clinical Trial

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection. To evaluate the effectiveness and safety of toripalimab compared with placebo combined with platinum-containing dual-drug chemotherapy.
Trial Details
NCT Number NCT04772287
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Non Small Cell Lung Cancer
Enrollment 341 participants
Start Date 2021-03-31
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2021-02-26